Prognostic factors in malignant pleural mesothelioma

Human Pathology

Volumn 46, Issue 6, 2015, Pages 789-804

  Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Diagnosis; Malignant mesothelioma; Prognosis; Therapeutic targets; Tumor markers

Indexed keywords

ANGIOPOIETIN 1; CAVEOLIN 1; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; DIPEPTIDYL PEPTIDASE IV; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE; LIVIN; MESOTHELIN; MESSENGER RNA; MIGRATION INHIBITION FACTOR; NAVELBINE; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PEMETREXED; PLATELET DERIVED GROWTH FACTOR AB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SURVIVIN; SYNDECAN 1; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS; BIOLOGICAL MARKER; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; PLEURA MESOTHELIOMA; PROGNOSIS; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PLEURAL NEOPLASMS;

BIOLOGICAL MARKERS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84937965569     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.02.006     Document Type: Article

References (124)

1. N.G. Ordóñez Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update Hum Pathol 44 2013 1 19
2. D.W. Henderson, G. Reid, S.C. Kao, N. van Zandwijk, and S. Klebe Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers J Clin Pathol 66 2013 847 853
3. P.G. Betta, C. Magnani, T. Bensi, N.F. Trincheri, and S. Orecchia Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma Arch Pathol Lab Med 136 2012 253 261
4. N.P. Campbell, and H.L. Kindler Update on malignant pleural mesothelioma Semin Respir Crit Care Med 32 2011 102 110
5. H.I. Pass, D. Giroux, C. Kennedy, and et al. IASLC Staging Committee and Participating Institutions. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee J Thorac Oncol 9 2014 856 864
6. K. Kadota, K. Suzuki, C. Colovos, and et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma Mod Pathol 25 2012 260 271
7. A.C. Tanrikulu, A. Abakay, M.A. Kaplan, and et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma Respiration 80 2010 480 487
8. S. Nojiri, K. Gemba, K. Aoe, and et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan Jpn J Clin Oncol 41 2011 32 39
9. B. Ghanim, M.A. Hoda, M.P. Winter, and et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis Ann Surg 256 2012 357 362
10. Z.H. Yao, G.Y. Tian, S.X. Yang, and et al. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma Tumour Biol 35 2014 6839 6845
11. B. Ghanim, M.A. Hoda, T. Klikovits, and et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma Br J Cancer 110 2014 984 990
12. J.K. Blayney, G.L. Ceresoli, B. Castagneto, and et al. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma Eur J Cancer 48 2012 2983 2992
13. B. Davidson New diagnostic and molecular characteristics of malignant mesothelioma Ultrastruct Pathol 32 2008 227 240
14. B.T. Mossman, A. Shukla, N.H. Heintz, C.F. Verschraegen, A. Thomas, and R. Hassan New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas Am J Pathol 182 2013 1065 1077
15. D. Jean, J. Daubriac, F. Le Pimpec-Barthes, F. Galateau-Salle, and M.C. Jaurand Molecular changes in mesothelioma with an impact on prognosis and treatment Arch Pathol Lab Med 136 2012 277 293
16. J.G. Edwards, D.E. Swinson, J.L. Jones, D.A. Waller, and K.J. O'Byrne EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma Lung Cancer 54 2006 399 407
17. R. Gaafar, A. Bahnassy, I. Abdelsalam, and et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma Lung Cancer 70 2010 43 50
18. O. Rena, L.R. Boldorini, E. Gaudino, and C. Casadio Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations J Surg Oncol 104 2011 701 705
19. A. Schramm, I. Opitz, S. Thies, and et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma Eur J Cardiothorac Surg 37 2010 566 572
20. G. Levallet, M. Vaisse-Lesteven, N. Le Stang, and et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group J Thorac Oncol 7 2012 599 606
21. D.J. Pinato, F.A. Mauri, T. Lloyd, and et al. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma Br J Cancer 108 2013 621 628
22. A.S. Tsao, N. Harun, J. Fujimoto, and et al. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma Ann Diagn Pathol 18 2014 140 145
23. S. Kumar-Singh, W. Jacobs, K. Dhaene, and et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome J Pathol 186 1998 300 305
24. B.W. Robinson, J. Creaney, R. Lake, and et al. Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 2003 1612 1616
25. R. Hassan, A.T. Remaley, M.L. Sampson, and et al. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer Clin Cancer Res 12 2006 447 453
26. A. Cristaudo, R. Foddis, A. Vivaldi, and et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer Clin Cancer Res 13 2007 5076 5081
27. B.D. Grigoriu, A. Scherpereel, P. Devos, and et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment Clin Cancer Res 13 2007 2928 2935
28. J. Schneider, H. Hoffmann, H. Dienemann, F.J. Herth, M. Meister, and T. Muley Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer J Thorac Oncol 3 2008 1317 1324
29. K. Hollevoet, K. Nackaerts, R. Gosselin, and et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma J Thorac Oncol 6 2011 1930 1937
30. M. Linch, S. Gennatas, S. Kazikin, and et al. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice BMC Cancer 14 2014 674
31. M. Alifano, M. Loi, S. Camilleri-Broet, S. Dupouy, J.F. Régnard, and P. Forgez Neurotensin expression and outcome of malignant pleural mesothelioma Biochimie 92 2010 164 170
32. M.M. Richardson, L.K. Jennings, and X.A. Zhang Tetraspanins and tumor progression Clin Exp Metastasis 28 2011 261 270
33. V.J. Amatya, Y. Takeshima, K. Aoe, and et al. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma Oncol Rep 29 2013 21 28
34. V.J. Amatya, Y. Takeshima, K. Kushitani, T. Yamada, C. Morimoto, and K. Inai Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines Oncol Rep 26 2011 1369 1375
35. K. Aoe, V.J. Amatya, N. Fujimoto, and et al. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma Clin Cancer Res 18 2012 1447 1456
36. S.C. Kao, N. Armstrong, B. Condon, and et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma Cancer 118 2012 2952 2961
37. C. Otterstrom, A. Soltermann, I. Opitz, and et al. CD74: a new prognostic factor for patients with malignant pleural mesothelioma Br J Cancer 110 2014 2040 2046
38. L. Righi, M.C. Cavallo, G. Gatti, and et al. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis Am J Clin Pathol 141 2014 816 827
39. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
40. A. Fassina, R. Cappellesso, V. Guzzardo, and et al. Epithelial-mesenchymal transition in malignant mesothelioma Mod Pathol 25 2012 86 99
41. H. Merikallio, P. Pääkkö, K. Salmenkivi, V. Kinnula, T. Harju, and Y. Soini Expression of snail, twist, and Zeb1 in malignant mesothelioma APMIS 121 2013 1 10
42. M. Kobayashi, C.L. Huang, M. Sonobe, and et al. Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas Ann Thorac Surg 95 2013 1181 1188
43. S.B. Watzka, U. Setinek, E.B. Stubenberger, and et al. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma Eur J Cardiothorac Surg 39 2011 180 184
44. J.G. Edwards, G. Cox, A. Andi, and et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma Br J Cancer 85 2001 863 868
45. S. Kumar-Singh, J. Weyler, M.J. Martin, P.B. Vermeulen, and E. Van Marck Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGFβ expression J Pathol 189 1999 72 78
46. L. Strizzi, A. Catalano, G. Vianale, and et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma J Pathol 193 2001 468 475
47. S.C. Kao, R. Harvie, F. Paturi, and et al. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine Lung Cancer 75 2012 248 254
48. C. Tabata, N. Hirayama, R. Tabata, and et al. A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Eur Respir J 36 2010 1099 1105
49. K. Yoneda, F. Tanaka, N. Kondo, and et al. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM) Ann Surg Oncol 19 2012 4229 4237
50. R. Filiberti, P. Marroni, M. Neri, and et al. Serum PDGF-AB in pleural mesothelioma Tumour Biol 26 2005 221 226
51. Y. Ohta, V. Shridhar, G.P. Kalemkerian, R.K. Bright, Y. Watanabe, and H.I. Pass Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma Cancer 85 1999 2570 2576
52. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
53. S.L. O'Kane, R.J. Pound, A. Campbell, N. Chaudhuri, M.J. Lind, and L. Cawkwell Expression of bcl-2 family members in malignant pleural mesothelioma Acta Oncol 45 2006 449 453
54. T.C. Mineo, V. Ambrogi, M.E. Cufari, and E. Pompeo May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg 38 2010 245 252
55. A.A. Bahnassy, A.R. Zekri, A.A. Abou-Bakr, and et al. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients Exp Mol Pathol 93 2012 154 161
56. M. Bongiovanni, P. Cassoni, P. De Giuli, and et al. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma Cancer 92 2001 1245 1250
57. F.D. Mairinger, R.F. Walter, S. Ting, and et al. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma Future Oncol 10 2014 995 1005
58. C.T. Chung, C. Santos Gda, D.M. Hwang, and et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma J Clin Pathol 63 2010 630 634
59. B. Nachmias, Y. Ashhab, and D. Ben-Yehuda The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer Semin Cancer Biol 14 2004 231 243
60. G.J. Gordon, M. Mani, L. Mukhopadhyay, and et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma J Pathol 211 2007 447 454
61. L. Kleinberg, A.K. Lie, V.A. Flørenes, J.M. Nesland, and B. Davidson Expression of inhibitors of apoptosis (IAP) family members in malignant mesothelioma Hum Pathol 38 2007 986 994
62. J. Hmeljak, N. Erčulj, V. Dolžan, and et al. Is survivin expression prognostic or predictive in malignant pleural mesothelioma? Virchows Arch 462 2013 315 321
63. J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero Development of PI3K inhibitors: lessons learned from early clinical trials Nat Rev Clin Oncol 10 2013 143 153
64. M.S. Song, L. Salmena, and P.P. Pandolfi The functions and regulation of the PTEN tumour suppressor Nat Rev Mol Cell Biol 13 2012 283 296
65. P. Cacciotti, D. Barbone, C. Porta, and et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure Cancer Res 65 2005 5256 5262
66. I. Opitz, A. Soltermann, M. Abaecherli, and et al. PTEN expression is a strong predictor of survival in mesothelioma patients Eur J Cardiothorac Surg 33 2008 502 506
67. V. Agarwal, A. Campbell, K.L. Beaumont, L. Cawkwell, and M.J. Lind PTEN protein expression in malignant pleural mesothelioma Tumour Biol 34 2012 847 851
68. B.K. Bitanihirwe, M. Meerang, M. Friess, and et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy J Thorac Oncol 9 2014 239 247
69. L. Mutti, M.T. Valle, B. Balbi, and et al. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes Int J Cancer 78 1998 740 749
70. C. Porta, M. Danova, A.M. Orengo, and et al. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro J Cell Physiol 185 2000 126 134
71. L. Calabrò, L. Sigalotti, E. Fonsatti, and et al. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications J Cell Physiol 226 2011 2595 2600
72. A.S. Mansfield, A.C. Roden, T. Peikert, and et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis J Thorac Oncol 9 2014 1036 1040
73. S.C. Kao, N. Pavlakis, R. Harvie, and et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
74. S.C. Kao, S. Klebe, D.W. Henderson, and et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy J Thorac Oncol 6 2011 1923 1929
75. D.J. Pinato, F.A. Mauri, R. Ramakrishnan, L. Wahab, T. Lloyd, and R. Sharma Inflammation-based prognostic indices in malignant pleural mesothelioma J Thorac Oncol 7 2012 587 594
76. O. Abakay, A.C. Tanrikulu, Y. Palanci, and A. Abakay The value of inflammatory parameters in the prognosis of malignant mesothelioma J Int Med Res 42 2014 554 565
77. T.M. Meniawy, J. Creaney, R.A. Lake, and A.K. Nowak Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma Br J Cancer 109 2013 1813 1820
78. B.M. Burt, S.J. Rodig, T.R. Tilleman, A.W. Elbardissi, R. Bueno, and D.J. Sugarbaker Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma Cancer 117 2011 5234 5244
79. K. Suzuki, K. Kadota, C.S. Sima, and et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients Cancer Immunol Immunother 60 2011 1721 1728
80. G. Alì, L. Boldrini, M. Lucchi, A. Mussi, V. Corsi, and G. Fontanini Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor J Thorac Oncol 4 2009 348 354
81. N.J. Curtin DNA repair dysregulation from cancer driver to therapeutic target Nat Rev Cancer 12 2012 801 817
82. L. Righi, M.G. Papotti, P. Ceppi, and et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy J Clin Oncol 28 2010 1534 1539
83. P.A. Zucali, E. Giovannetti, A. Destro, and et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin Clin Cancer Res 17 2011 2581 2590
84. Z.G. Zimling, J.B. Sørensen, T.A. Gerds, C. Bech, C.B. Andersen, and E. Santoni-Rugiu A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma Cancer Chemother Pharmacol 70 2012 743 754
85. N. Erčulj, V. Kovač, J. Hmeljak, and V. Dolžan The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma Ann Oncol 23 2012 961 967
86. N. Erčulj, V. Kovač, J. Hmeljak, A. Franko, M. Dodič-Fikfak, and V. Dolžan DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy J Thorac Oncol 7 2012 1609 1617
87. S. Ting, F.D. Mairinger, T. Hager, and et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma Clin Lung Cancer 14 2013 558 567
88. D.C. Christoph, B.R. Asuncion, C. Mascaux, and et al. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma J Thorac Oncol 7 2012 1440 1448
89. D.E. Lustgarten, C. Deshpande, C. Aggarwal, and et al. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma J Thorac Oncol 8 2013 469 477
90. A. Dejmek, U. Brockstedt, and A. Hjerpe Immunoreactivity of pleural malignant mesotheliomas to glutathione S-transferases APMIS 106 1998 489 494
91. K. Segers, S. Kumar-Singh, J. Weyler, and et al. Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study J Cancer Res Clin Oncol 122 1996 619 624
92. K. Segers, S.K. Singh, A. Van Daele, and et al. Evaluation and prognostic value of DNA content and of morphometric parameters in malignant mesothelioma using digital image analysis Lung Cancer 14 1996 229 237
93. P.Y. Wai, and P.C. Kuo Osteopontin: regulation in tumor metastasis Cancer Metastasis Rev 27 2008 103 118
94. K.X. Wang, and D.T. Denhardt Osteopontin: role in immune regulation and stress responses Cytokine Growth Factor Rev 19 2008 333 345
95. H.I. Pass, D. Lott, F. Lonardo, and et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels N Engl J Med 353 2005 1564 1573
96. S. Cappia, L. Righi, D. Mirabelli, and et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma Am J Clin Pathol 130 2008 58 64
97. H. Schouwink, C.M. Korse, J.M. Bonfrer, A.A. Hart, and P. Baas Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma Lung Cancer 25 1999 25 32
98. S.L. O'Kane, L. Cawkwell, A. Campbell, and M.J. Lind Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma Eur J Cancer 41 2005 1645 1648
99. G. Pinton, E. Brunelli, B. Murer, and et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma Cancer Res 69 2009 4598 4604
100. C.J. Jennings, A. O'Grady, R. Cummins, and et al. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma J Thorac Oncol 7 2012 243 248
101. P.M. Lindholm, Y. Soini, M. Myllärniemi, and et al. Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma J Clin Pathol 62 2009 339 344
102. A. Thylén, A. Hjerpe, and G. Martensson Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma Cancer 92 2001 1224 1230
103. J. Creaney, I.M. Dick, A. Segal, A.W. Musk, and B.W. Robinson Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma Lung Cancer 82 2013 491 498
104. J. Creaney, I.M. Dick, T.M. Meniawy, and et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma Thorax 69 2014 895 902
105. A. Baldi, M. Mottolese, B. Vincenzi, and et al. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma Pharmacogenomics 9 2008 1069 1077
106. L.E. Dalton, H.J. Clarke, J. Knight, and et al. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma Br J Cancer 108 2013 1340 1347
107. S. Crispi, R.A. Calogero, M. Santini, and et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target PLoS One 4 2009 e7016
108. A. Destro, G.L. Ceresoli, E. Baryshnikova, and et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up Lung Cancer 59 2008 369 376
109. S. Cedrés, M.A. Montero, E. Zamora, and et al. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma Clin Transl Oncol 16 2014 776 782
110. C. Tabata, E. Shibata, R. Tabata, and et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma BMC Cancer 13 2013 205
111. E. Giroux Leprieur, T. Hirata, M. Mo, and et al. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma Lung Cancer 85 2014 465 471
112. L. Arzt, F. Quehenberger, I. Halbwedl, T. Mairinger, and H.H. Popper BAP1 protein is a progression factor in malignant pleural mesothelioma Pathol Oncol Res 20 2014 145 151
113. G.J. Gordon, R.V. Jensen, L.L. Hsiao, and et al. Using gene expression ratios to predict outcome among patients with mesothelioma J Natl Cancer Inst 95 2003 598 605
114. G.J. Gordon, G.N. Rockwell, P.A. Godfrey, and et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma Clin Cancer Res 11 2005 4406 4414
115. G.J. Gordon, L. Dong, B.Y. Yeap, and et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma J Natl Cancer Inst 101 2009 678 686
116. F. López-Ríos, S. Chuai, R. Flores, and et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction Cancer Res 66 2006 2970 2979
117. H.I. Pass, Z. Liu, A. Wali, and et al. Gene expression profiles predict survival and progression of pleural mesothelioma Clin Cancer Res 10 2004 849 859
118. A. de Reyniès, M.C. Jaurand, A. Renier, and et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition Clin Cancer Res 20 2014 1323 1334
119. H.I. Pass, C. Goparaju, S. Ivanov, and et al. hsa-miR-29c∗is linked to the prognosis of malignant pleural mesothelioma Cancer Res 70 2010 1916 1924
120. R. Bueno, A. De Rienzo, L. Dong, and et al. Second generation sequencing of the mesothelioma tumor genome PLoS One 5 2010 e10612
121. T. Shukuya, M. Serizawa, M. Watanabe, and et al. Identification of actionable mutations in malignant pleural mesothelioma Lung Cancer 86 2014 35 40
122. G. Guo, J. Chmielecki, C. Goparaju, and et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma Cancer Res 75 2015 264 269
123. Y. Yoshikawa, A. Sato, T. Tsujimura, and et al. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes Int J Cancer 136 2015 560 571
124. P. Kumar, and R.A. Kratzke Molecular prognostic markers in malignant mesothelioma Lung Cancer 49 Suppl. 1 2005 S53 S60